Key Takeaways
- Wellumio closed an oversubscribed US$9.75 million pre‑Series A round, bringing in new international investors Bioshore Ventures (Australia) and Jumpspace Ventures (U.S.).
- The round was led by Nuance Connected Capital, with additional backing from Icehouse Ventures, NZ Growth Capital Partners’ Aspire Seed Fund, Pacific Channel, Booster, Cure Kids Ventures, angel groups Flying Kiwi and Enterprise Angels, and retail investors via Snowball Effect.
- Funds will accelerate clinical validation, regulatory approvals, and commercial rollout of Wellumio’s portable Axana MRI‑based stroke scanner.
- Leadership has been bolstered by the appointment of Harry Marfatia as Head of Finance, strengthening financial and operational capabilities.
- The Axana scanner weighs 50 kg, is battery‑powered, and requires no contrast agents, cryogenics, or shielded rooms, enabling point‑of‑care neuroimaging in emergency settings.
- Its core technology—Pulsed Gradient Free Mapping (PGFM)—secured a U.S. patent in December 2025 and has shown concordance with conventional MRI for key stroke biomarkers in preclinical and first‑in‑human studies.
- Wellumio aims to move swiftly through clinical trials, regulatory pathways, and commercial launch to reduce stroke‑related disability by delivering faster diagnosis.
Funding Round Overview
Wellumio announced the final close of an oversubscribed pre‑Series A financing round totaling US$9.75 million. The capital infusion is earmarked for expanding the company’s team, enhancing technical capabilities, and pushing forward clinical, regulatory, and commercial milestones across additional sites and geographies. The oversubscription reflects strong investor confidence in Wellumio’s mission to transform acute stroke care through portable, AI‑enhanced MRI technology. By securing this amount, the startup gains the financial runway needed to advance product development while maintaining flexibility for unforeseen challenges in the medtech landscape.
Investor Composition and Strategic Value
The round welcomed two new international investors: Australian medtech specialist Bioshore Ventures and early‑stage U.S. venture firm Jumpspace Ventures. Their participation broadens Wellumio’s global investor base and brings complementary expertise—Bioshore’s deep knowledge of medical device commercialization in the Asia‑Pacific region and Jumpspace’s experience scaling early‑stage health‑tech startups in North America. Existing backers Nuance Connected Capital (lead investor), Icehouse Ventures, NZ Growth Capital Partners’ Aspire Seed Fund, Pacific Channel, Booster, and Cure Kids Ventures continued their support. Angel groups Flying Kiwi and Enterprise Angels contributed through New Zealand’s Active Investor Plus (AIP) programme, while retail investors accessed the round via the Snowball Effect platform, diversifying the funding sources and aligning with both institutional and grassroots enthusiasm.
CEO Vision on Stroke Care Urgency
Shieak Tzeng, co‑founder and CEO of Wellumio, emphasized the critical timing inherent in stroke intervention: “Every minute counts in stroke care, yet only a small proportion of patients receive treatment within the ‘golden hour’, when timely intervention offers the best chance of reducing long‑term disability.” He highlighted that Wellumio’s portable, AI‑enhanced MRI‑based brain imaging technology is purpose‑built to detect acute stroke at the point of care, enabling clinicians to make faster treatment decisions when seconds matter. Tzeng noted that the additional investment, coupled with the expertise and international networks of the new investors, will accelerate the company’s clinical validation, regulatory, and commercial pathways, moving the technology closer to the healthcare providers and patients who need it most.
Leadership Strengthening
To support its accelerated growth trajectory, Wellumio has reinforced its executive team with the appointment of Harry Marfatia as Head of Finance. Marfatia brings extensive senior‑level experience in medtech financial management, having previously overseen budgeting, fundraising, and financial reporting for several high‑growth healthcare technology firms. His role will be pivotal in building the financial infrastructure necessary to advance clinical validation, drive product development, and execute commercialisation strategies. The addition of a seasoned finance leader signals Wellumio’s commitment to establishing robust governance and operational discipline as it transitions from a promising startup to a scalable commercial enterprise.
Axana Scanner: Portable Point‑of‑Care MRI
At the core of Wellumio’s offering is the Axana scanner, a portable, battery‑powered brain imaging device weighing just 50 kilograms. Unlike conventional MRI systems, Axana eliminates the need for contrast agents, cryogenic cooling, or shielded rooms, making it feasible to deploy directly within emergency departments, ambulances, or other acute care settings where space and infrastructure are limited. This portability aims to bring rapid neuroimaging to the bedside, drastically reducing the time between symptom onset and diagnostic imaging—a crucial factor in improving stroke outcomes. The design reflects a deliberate focus on usability, durability, and clinical workflow integration, positioning Axana as a practical solution for hospitals striving to meet time‑critical stroke care benchmarks.
Proprietary PGFM Technology and Patent Milestone
The Axana scanner leverages Wellumio’s proprietary Pulsed Gradient Free Mapping (PGFM) technology, which was granted a U.S. patent in December 2025. PGFM enables high‑quality brain imaging without the conventional reliance on strong, rapidly switching gradient fields, thereby simplifying hardware requirements and lowering power consumption. Preclinical studies and first‑in‑human feasibility trials have demonstrated that PGFM‑based imaging agrees closely with standard MRI across key stroke biomarkers such as diffusion restriction, perfusion deficits, and hemorrhage detection. These results provide a strong scientific foundation for Wellumio’s continued clinical development, reinforcing confidence that the technology can deliver diagnostic fidelity comparable to established hospital‑based MRI while retaining its portable advantages.
Clinical Validation and Regulatory Pathway
Wellumio’s immediate focus is to advance Axana through rigorous clinical validation studies that will substantiate its safety, efficacy, and diagnostic accuracy in diverse patient populations. The company plans to conduct multi‑site trials spanning emergency departments, stroke centers, and rural health facilities to capture real‑world performance data. Parallel to these efforts, Wellumio is engaging with regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to navigate the clearance process for a novel point‑of‑care MRI device. The freshly secured funding will support trial execution, data analysis, and the preparation of comprehensive regulatory submissions, aiming to secure market approval within the next 24‑36 months.
Commercialization Strategy and Market Impact
Beyond regulatory clearance, Wellumio intends to execute a phased commercialization strategy that begins with targeted launches in high‑volume stroke centers in the United States, Europe, and Australia, followed by broader rollout to secondary and tertiary care hospitals. The company will leverage the commercial expertise of its investors—particularly Bioshore Ventures’ Asia‑Pacific network and Jumpspace Ventures’ U.S. go‑to‑market experience—to establish distribution channels, forge partnerships with hospital systems, and develop reimbursement pathways. By enabling rapid stroke diagnosis at the point of care, Wellumio anticipates reducing door‑to‑needle times, lowering rates of long‑term disability, and ultimately decreasing the economic burden associated with stroke care on healthcare systems worldwide.
Future Outlook and Broader Implications
Looking ahead, Wellumio’s success could reshape the landscape of acute neuroimaging, making MRI‑level diagnostics accessible in settings previously reliant on CT scans or clinical assessment alone. The portability and AI‑enhanced analytics of Axana may also open avenues for applications beyond stroke, such as traumatic brain injury, intracranial hemorrhage monitoring, and neurodegenerative disease screening. As the company progresses through its clinical, regulatory, and commercial milestones, the continued backing of a diverse, international investor coalition will be instrumental in scaling operations, attracting top talent, and fulfilling the vision of delivering timely, life‑saving brain imaging to patients wherever they need it most.